SRR600385
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INFLAMMATORY_RESPONSE+0.483
- ALLOGRAFT_REJECTION+0.482
- INTERFERON_ALPHA_RESPONSE+0.444
- IL6_JAK_STAT3_SIGNALING+0.442
- INTERFERON_GAMMA_RESPONSE+0.438
- KRAS_SIGNALING_UP+0.402
- UV_RESPONSE_DN+0.391
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.387
- ANGIOGENESIS+0.386
- COMPLEMENT+0.384
Top 10 suppressed
- MYC_TARGETS_V2-0.574
- MYC_TARGETS_V1-0.548
- DNA_REPAIR-0.544
- UNFOLDED_PROTEIN_RESPONSE-0.445
- E2F_TARGETS-0.440
- OXIDATIVE_PHOSPHORYLATION-0.383
- G2M_CHECKPOINT-0.377
- WNT_BETA_CATENIN_SIGNALING-0.376
- MTORC1_SIGNALING-0.274
- MITOTIC_SPINDLE-0.265
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR607935 | GTEX | — | 0.953 |
| 2 | SRR607647 | GTEX | — | 0.953 |
| 3 | R232 | — | — | 0.950 |
| 4 | SRR607406 | GTEX | — | 0.931 |
| 5 | SRR1499630 | GTEX | — | 0.931 |
| 6 | BS_1KYGSMA7 | low-grade glioma | — | 0.929 |
| 7 | SRR1334033 | GTEX | — | 0.925 |
| 8 | MDT-AP-2638 | Med | Medulloblastoma | 0.923 |
| 9 | ERR2598337 | fetal | fetal | 0.921 |
| 10 | BS_3XY76V8T | Ganglioglioma | — | 0.920 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INFLAMMATORY_RESPONSE | 0.483 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.482 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.444 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.442 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.438 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.402 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.391 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.387 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.386 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.384 | Inavolisib | — uncovered |
| MYOGENESIS | 0.381 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.364 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.318 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.305 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.290 | Temsirolimus | — uncovered |
| COAGULATION | 0.284 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.275 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.215 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.201 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.201 | Inavolisib | — uncovered |